番茄社区app

Meeting Coverage >

ASCO

'Practice Changing' Trial for Inoperable Locally Advanced NSCLC

EGFR testing now needed for all patients with stage III disease, experts say

Intralesional Therapy for Melanoma Effective, May Have Systemic Activity

Preoperative antibody fusion daromun significantly reduced relapse versus upfront surgery

Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma

Second belantamab mafodotin-containing triplet to show potency in this setting

Virtual and In-Person Palliative Care Equally Beneficial in Advanced Lung Cancer

No differences observed in quality of life metric, patient and caregiver satisfaction

No Survival Advantage With Sacituzumab Over Chemo in Previously Treated NSCLC

Results are "disappointing as we need better therapies in the refractory space," expert says

Subcutaneous Amivantamab Plus Lazertinib Non-Inferior to IV Dosing in NSCLC

Unexpectedly offers a possible overall survival benefit, researchers say

Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agents

China-based trial may present a hurdle to FDA approval, however

Kinder, Gentler Regimen for Classical Hodgkin Prevails in Randomized Trial

Better efficacy with brentuximab vedotin versus standard chemo, substantially less toxicity

STAMP Inhibitor Tops Imatinib, Second-Gen TKIs for Newly Diagnosed CML

The benefit-risk profile could change the treatment paradigm in CML, expert says

Unprecedented PFS Results in ALK-Positive Lung Cancer Trial

"We have not seen anything close to this," says expert

HPV Vaccination Reduces Risk of Multiple Types of Cancer in Men and Women

Large cohort study provides some of the first evidence of cancer reduction after vaccination

Most Women Can Have Successful Pregnancies After Breast Cancer Treatment

Fertility preservation before treatment strongly predictive of live births, study shows

Estrogen-Only Therapy for Menopausal Symptoms Increases Ovarian Cancer Risk

Incidence, mortality double over 20 years, while estrogen plus MPA lowers endometrial cancer risk

TTFields Therapy Yields OS Improvement in Second-Line NSCLC

However, device was not tested alongside current standard of care, expert points out

Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer

No PFS, OS benefit with first-line versus second-line CDK4/6 inhibition, more toxicity, cost

Skipping Radiotherapy 'Seems Safe' for PMBCL Patients in Remission

PET-negative patients after chemoimmunotherapy fared well with observation alone

FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer

Survival benefit supports FGFR testing for all patients with metastatic disease, researcher says

Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLC

"Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert

Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Years

Retrospective study finds no difference in OS between patients who stop and those who continue

No Survival Benefit With Immune Checkpoint Inhibitor Rechallenge in Metastatic RCC

The strategy also led to increased toxicity

New Data in NSCLC Bolster Support for Perioperative Immunotherapy

EFS benefit with pembrolizumab in KEYNOTE-671, but no OS benefit "yet," says investigator

Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma

The CAR T-cell therapy led to significantly longer overall survival

New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials

High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents

CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma

Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets

T-DXd Proves Mettle in Multiple Solid Tumors

Data from ongoing DPT02 trial show broad activity in HER2-expressing advanced disease

Omitting RT Safe in Many Locally Advanced Rectal Cancers

Most intermediate-risk cases can be cured without pelvic radiation, says investigator

Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Glioma

INDIGO data demonstrate that some patients can delay "toxic" chemo and radiation, says expert

Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma

SWOG trial had goal of "harmonizing" treatment in adults, children with advanced-stage disease

New Standard in Operable EGFR-Positive Lung Cancer

"We should firmly close the door on one-size-fits-all treatment," says ASCO expert

New Ovarian Cancer Drug Extends Survival in Resistant Disease

"Practice changing" findings for tough-to-treat patient population

Neoadjuvant Chemo Flops Versus Upfront Surgery for Resectable Pancreatic Cancer

Survival 13 months better with surgery, but "curiosities" in neoadjuvant arm muddy the results

Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancer

Response rates reached 41-47% with different approaches in rare disease

Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer

Impressive 3-year invasive DFS seen with adaptive response strategy using FDG-PET

Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancer

Questions about anti-PD-L1 contribution, cost, and access to durvalumab, bevacizumab, olaparib

De-Escalated Surgery Suffices for Low-Risk Cervical Cancer

Simple hysterectomy non-inferior to radical operation

CDK4/6 Extends Reach Into Early-Stage Breast Cancer

Addition of ribociclib to endocrine therapy boosts disease-free survival in high-risk disease

Medicaid Expansion Tied to Better Outcomes in Black Patients With GI Cancers

Two-year mortality decreased for three types of GI cancer in expansion vs non-expansion states

Less-Invasive Surgery for Pancreatic Cancer Proves Safe, Effective

Radical resection rate noninferior to open surgery in early-stage disease, with similar survival

Monoclonal Antibody Reduced Need For Transfusions in Low-Risk MDS

Results suggest a "paradigm shift" in the treatment of anemia for these patients

Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patients

5-year OS increased to 100% in standard-risk ALL patients at a Tijuana hospital

1